Brief: Kiniksa Announces Phase 3 Trial Of Mavrilimumab In Covid-19-Related ARDS Did Not Meet Primary Efficacy Endpoint

Kiniksa Pharmaceuticals International

28/12/2021 12:06

Dec 28 (Reuters) - Kiniksa Pharmaceuticals Ltd  KNSA.O :
    * KINIKSA ANNOUNCES RESULTS FROM PHASE 3 TRIAL OF
MAVRILIMUMAB IN
COVID-19-RELATED ARDS
    * KINIKSA PHARMACEUTICALS LTD -  PHASE 3 TRIAL OF
MAVRILIMUMAB IN
COVID-19-RELATED ARDS DID NOT MEET PRIMARY EFFICACY ENDPOINT
    * KINIKSA - PHASE 3 PORTION OF TRIAL DID NOT MEET PRIMARY
EFFICACY
ENDPOINT OF PROPORTION OF PATIENTS ALIVE AND FREE OF MECHANICAL
VENTILATION AT DAY 29

Source text for Eikon:  ID:nGNX9pmy7M 
Further company coverage:  KNSA.O 

 ((Reuters.Briefs@thomsonreuters.com;;))